

Coronavirus Disease 2019 (COVID-19) Vaccine Guidance

PFIZER-BioNtech

On August 23, 2021, the Food and Drug Administration (FDA) approved the first COVID-19 vaccine. The vaccine has been known as the Pfizer-BioNTech COVID-19 Vaccine, and will now be marketed as Comirnaty (koe-mir'-na-tee), for the prevention of COVID-19 disease in individuals 16 years of age and older. The vaccine also continues to be available under emergency use authorization (EUA), including for individuals 5 through 15 years of age and for the administration of a third dose in certain immunocompromised individuals.

91300	SARSCOV2 VAC 30MCG/0.3ML IM	Pfizer	Pfizer-Biontech Covid-19 Vaccine	12/11/2020
0001A	ADM SARSCOV2 30MCG/0.3ML 1ST	Pfizer	Pfizer-Biontech Covid-19 Vaccine Administration – First Dose	12/11/2020
0002A	ADM SARSCOV2 30MCG/0.3ML 2ND	Pfizer	Pfizer-Biontech Covid-19 Vaccine Administration – Second Dose	12/11/2020
0003A	ADM SARSCOV2 30MCG/0.3ML 3RD	Pfizer	Pfizer-Biontech Covid-19 Vaccine Administration – Third Dose	8/12/2021
0004A	30 mcg/0.3 mL dosage, diluent reconstituted	Pfizer	Pfizer-Biontech Covid-19 Vaccine Administration – Booster Dose	9/22/2021

MODERNA

On December 19, 2020, the Vaccines and Related Biological Products Advisory Committee met in open session and approved Emergency Use Authorization (EUA) of the Moderna Inc. COVID-19 Vaccine for the prevention of COVID-19 in individuals 18 years and older.

Coronavirus Disease 2019 (COVID-19) Vaccine Guidance

MODERNA (continued)

91301	SARSCOV2 VAC 100MCG/0.5ML IM	Moderna	Moderna Covid-19 Vaccine	12/11/2020
0011A	ADM SARSCOV2 100MCG/0.5ML1ST	Moderna	Moderna Covid-19 Vaccine Administration – First Dose	12/11/2020
0012A	ADM SARSCOV2 100MCG/0.5ML2ND	Moderna	Moderna Covid-19 Vaccine Administration – Second Dose	12/11/2020
0013A	ADM SARSCOV2 100MCG/0.5ML3RD	Moderna	Moderna Covid-19 Vaccine Administration – Third Dose	8/12/2021
91306	50 mcg/0.25 mL dosage	Moderna	Moderna Covid-19 Vaccine – Intramuscular Use	10/20/2021
0064A	50 mcg/0.25 mL dosage	Moderna	Moderna Covid-19 Vaccine – Booster Dose	10/20/2021

Johnson & Johnson

On February 26, 2021, the Vaccines and Related Biological Products Advisory Committee met in open session and approved Emergency Use Authorization (EUA) of the Johnson & Johnson COVID-19 Vaccine for the prevention of COVID-19 in individuals 18 years and older.

91303	SARSCOV2 VAC AD26 .5ML Janssen COVID-19 Vaccine	Johnson & Johnson	Johnson & Johnson Covid-19 Vaccine	2/27/2021
0031A	ADM SARSCOV2 VAC AD26 .5ML Janssen COVID-19	Johnson & Johnson	Johnson & Johnson Covid-19 Vaccine	2/27/2021
0034A	5x10 ¹⁰ viral particles/0.5 mL dosage	Johnson & Johnson	Johnson & Johnson Covid-19 Vaccine - Booster Dose	2/27/2021

Coronavirus Disease 2019 (COVID-19)

Frequently Asked Questions - providers

Member Cost-share: No member cost share will be charged, per the CARES Act. COVID-19 vaccines will be covered under the preventive benefit for both in- and out-of-network providers.

Billing: Providers may bill the vaccine administration fee effective December 10, 2020. The provider should use the claim form appropriate for the services billed. Optima Health will follow standard CMS guidelines for billing vaccine administration.

At this time, both COVID-19 vaccine doses and their administration costs will be covered in full for members under their preventive benefit, both in and out of network.

At this time, self-funded employers will pay for the administration of the COVID-19 vaccine, but not for the vaccine itself, per current [CMS guidance](#). Vaccines may be covered under the medical or pharmacy benefit, and will appear in claims experience data similar to other vaccines.

Note: For Medicare Advantage and D-SNP members, please bill Medicare fee for service per CMS guidance

Vaccine Supplies: The Virginia Department of Health (VDH) is handling the distribution of the vaccine through its priority system. Visit vdh.virginia.gov to access and submit the form. VDH will determine prioritization of the provider or facility.

Optima Health is closely monitoring the spread of the coronavirus (COVID-19) in the United States and its presence in Virginia. We have enacted our robust emergency management protocols and our dedicated team is on standby to monitor and follow COVID-19 closely in Virginia and North Carolina. If you have additional questions, please contact your **Network Educator at (877) 865-9075, Option 2.**

Learn about actions we are taking to support our members at: optimahealth.com/covid-19.

View the latest version of our [provider FAQs](#).

Note: Optima Family Care and Optima Health Community Care Plans:

- The Department of Medical Assistance Services (DMAS) has waived certain program requirements, including specified service authorizations and prescription drug limitations and has also waived specific provider requirements, including some that are laid out in these FAQs.
- Please refer to all guidance issued by DMAS which can be found at: <https://www.dmas.virginia.gov/#/emergencywaiver>
- DMAS added new guidance on 11/23/2021.
- Medicaid or FAMIS member co-pays have been eliminated, effective March 13, 2020. No co-pay will be collected from any Medicaid or FAMIS member in order to encourage all members to receive medical care and treatment. This co-payment suspension shall apply until the end of this health emergency and upon notice from the Department.
- In regards to DBHDS Updates and Guidance: DBHDS COVID-19 Resource Page is being regularly updated: <http://www.dbhds.virginia.gov/covid19> and it includes CSB Functional and Operational Guidance.